BOSTON & MONTREAL – enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company today announced that management will participate in the following investor conferences:
enGene to Host Virtual KOL Event to Discuss Emerging Non-Muscle Invasive Bladder Cancer (NMIBC) Market Insights, on August 11, 2026
BOSTON & MONTREAL – enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that it will host a virtual key opinion leader
enGene Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones
Michael Heffernan assumes the role of Chairman of the Board Dr. Richard Glickman to step down Pre-Biologics License Application (BLA) meeting with the FDA planned for 2H 2026 Initiation of
enGene Reports Second Quarter 2026 Financial Results and Provides Business Update
12-month complete response data from LEGEND pivotal cohort and subsequent FDA engagement planned for 2H 2026 Initiation of Biologics License Application (BLA) filing for detalimogene planned for 2H 2026 First
enGene Announces Updated Interim Results From LEGEND Pivotal Cohort
54% complete response (CR) rate at any time; 43% six month CR rate Low rate of progression to muscle-invasive or higher disease (3.2%) Low percentage of patients experienced treatment-related adverse
enGene Announces Name Change to enGene Therapeutics Inc.
Name change reflects transition towards potential commercial organization in 2027 Planned Biologics License Application (BLA) submission for detalimogene in 2H 2026 BOSTON & MONTREAL – enGene Therapeutics Inc. (formerly, enGene
enGene Reports First Quarter 2026 Financial Results and Provides Business Update
LEGEND pivotal cohort update planned for a spring 2026 medical conference 12-month complete response data from LEGEND pivotal cohort expected in 2H 2026 Biologics License Application (BLA) submission for detalimogene
enGene to Participate in Upcoming Investor Conferences
BOSTON & MONTREAL – enGene Holdings Inc. (Nasdaq: ENGN or “enGene”), a clinical-stage, non-viral genetic medicines company, today announced that management will participate in the following investor conferences: Oppenheimer 36th
enGene to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
BOSTON & MONTREAL – enGene Holdings Inc. (Nasdaq: ENGN or “enGene”), a clinical-stage, non-viral genetic medicines company, today announced that Ron Cooper, President and Chief Executive Officer, will participate in
enGene Announces Expanded $125 Million Debt Facility with Hercules Capital, Inc.
Up to $100 million in additional loan proceeds provide additional financial flexibility to advance detalimogene development and commercialization for bladder cancer $25 million advanced at close of the amendment to
